Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C D Jurincic

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Seminars in Oncology|October 1, 1991
Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized studyC D Jurincic, R Horlbeck, K F Klippel
European Urology|June 1, 2000
Efficacy of prophylactic Immucothel in patients pretreated with conventional drugs to prevent recurrence of superficial bladder carcinomaC Echarti, C D Jurincic-Winkler, K F Klippel
The Journal of Urology|April 1, 1988
Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized studyC D Jurincic, U Engelmann, J Gasch, et al.
Archivos Espanoles De Urologia|May 1, 1987
[Immunotherapy use of keyhole-limpet hemocyanin in the treatment of bladder cancer. Preliminary study]C D Jurincic, U Engelman, J Gasch, et al.
Urologia Internationalis|January 1, 1990
Prostate-specific antigen in prostatic carcinomaC D Jurincic, H U Pixberg, A Gasser, et al.
European Urology|June 1, 2000
Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up studyC D Jurincic-Winkler, K A Metz, J Beuth, et al.
Anticancer Research|July 1, 1996
Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinomaC D Jurincic-Winkler, H von der Kammer, J Beuth, et al.
Wiener Klinische Wochenschrift|January 1, 1994
[Adjuvant immunotherapy with keyhole limpet hemocyanin in category PT 2 N+ and PT 3-4, No-N+, Mo renal cell carcinoma]C D Jurincic-Winkler, R Horlbeck, H von der Kammer, et al.
European Urology|January 1, 1995
Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladderC D Jurincic-Winkler, H Gallati, M Alvarez-Mon, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Seminars in Oncology|October 1, 1991
Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized studyC D Jurincic, R Horlbeck, K F Klippel
European Urology|June 1, 2000
Efficacy of prophylactic Immucothel in patients pretreated with conventional drugs to prevent recurrence of superficial bladder carcinomaC Echarti, C D Jurincic-Winkler, K F Klippel
The Journal of Urology|April 1, 1988
Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized studyC D Jurincic, U Engelmann, J Gasch, et al.
Archivos Espanoles De Urologia|May 1, 1987
[Immunotherapy use of keyhole-limpet hemocyanin in the treatment of bladder cancer. Preliminary study]C D Jurincic, U Engelman, J Gasch, et al.
Urologia Internationalis|January 1, 1990
Prostate-specific antigen in prostatic carcinomaC D Jurincic, H U Pixberg, A Gasser, et al.
European Urology|June 1, 2000
Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up studyC D Jurincic-Winkler, K A Metz, J Beuth, et al.
Anticancer Research|July 1, 1996
Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinomaC D Jurincic-Winkler, H von der Kammer, J Beuth, et al.
Wiener Klinische Wochenschrift|January 1, 1994
[Adjuvant immunotherapy with keyhole limpet hemocyanin in category PT 2 N+ and PT 3-4, No-N+, Mo renal cell carcinoma]C D Jurincic-Winkler, R Horlbeck, H von der Kammer, et al.
European Urology|January 1, 1995
Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladderC D Jurincic-Winkler, H Gallati, M Alvarez-Mon, et al.
Pageof 1